This is the authors' abstract. We don't add key points for this paper.
The current work proposes a particular, accurate, simple, and speedy HPLC approach for detecting impurities in Bilastine (BLS) tablet formulations. A gradient mode elution buffer solution (10 mm Potassium dihydrogen phosphate and 10 mm Di-Potassium hydrogen phosphate) employed as mobile phase-A, acetonitrile used as as mobile phase-B, facilitating optimized chromatographic separation with X Bridge Shield RP18 (150 × 4.6 mm) 3.5 μm column. The detection was performed at 254 nm using a 10 μL injection volume, 40 °C column temperature, and 1.0 mL/min flow rate. The method was validated using the current regulatory guidelines. The recovery for impurities found between 94.4 and 107.2, with precision data ranging from 0.53 to 1.97. The impurities were linear, with correlation coefficient values greater than 0.999. Specificity was proven with degradants and the method stability indication nature was proven by forced degradation studies in-line with regulatory guidelines. Quality by design concept was utilized to demonstrate the method robustness. Solution stability established up to 72 h for using the solutions for longer times. The validation results show that the suggested approach is specific, accurate, linear, precise, rugged, and resilient for quantifying impurities in tablet formulation. • Established for qualitative and quantitative determination of Bilastine-related compounds. • The findings are within the boundaries of the validation parameters. • The first QbD-based chromatographic approach for simultaneously quantifying five impurities. • Straightforward, specific, and sensitive, and a shorter runtime.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sasikala et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: